SCLERAXIS AS A PROGNOSTIC MARKER OF MYOCARDIAL FIBROSIS IN HYPERTROPHIC CARDIOMYOPATHY (SPARC) STUDY
Antonia Zhu(St. Boniface Hospital), Davinder S. Jassal(St. Boniface Hospital), Chantal Asselin, Hilary Bews(University of Manitoba), Vineet Goyal(Columbia University), Ishika Mittal(St. Boniface Hospital), Ian Kirkpatrick(University of Leeds), Raghu S. Nagalingam(St. Boniface Hospital), David Cheung(St. Boniface Hospital), Michael P. Czubryt(St. Boniface Hospital)
Cited by 0
Related Papers
MEF2C Transcription Factor Controls Chondrocyte Hypertrophy and Bone Development
|Developmental Cell|2007|457
Regulation of peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) and mitochondrial function by MEF2 and HDAC5
|Proceedings of the National Academy of Sciences|2003|419
Requirement for serum response factor for skeletal muscle growth and maturation revealed by tissue-specific gene deletion in mice
|Proceedings of the National Academy of Sciences|2005|296
Cardiac Fibroblast Activation Post-Myocardial Infarction: Current Knowledge Gaps
|Trends in Pharmacological Sciences|2017|204
Targeting the renin-angiotensin-aldosterone system in fibrosis
|Matrix Biology|2020|187